Clinical Trial

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Study acronym: ACTengine
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Protocol Amendment History 33 amendments
This ClinicalTrials.gov record has been amended 33 times since 2018-09-25; most recent amendment 2026-05-12.
Status change: Not Yet Recruiting → Recruiting 2019-04-22
Trial Details
NCT Number NCT03686124
Lead Sponsor Immatics US, Inc.
Conditions Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
Enrollment 375 participants
Start Date 2019-05-14
Primary Completion 2028-12 (estimated)
Study Completion 2032-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-13